Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 31.
doi: 10.1007/7854_2024_559. Online ahead of print.

Informed Consent in Psychedelic-Assisted Therapy

Mazdak M Bradberry  1 , Paul S Appelbaum  2 , Natalie Gukasyan  2
Affiliations

Informed Consent in Psychedelic-Assisted Therapy

Mazdak M Bradberry et al. Curr Top Behav Neurosci. .

Abstract

Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed "psychedelics," for therapeutic purposes in Western clinical settings. Care in these settings is governed by standards for the communication and assumption of risk in the process of informed consent. Rigorous informed consent standards in psychedelic medicine are not only essential for quality care but also critical to the mitigation of risk, particularly in research settings and for vulnerable individuals. This chapter describes practical elements of informed consent in psychedelic therapy, with a focus on effective communication of the risks and potential benefits of classical psychedelic and entactogen treatments as they are currently understood.

Keywords: Informed consent; MDMA; Psilocybin; Psychedelic; Risk–benefit.

PubMed Disclaimer

References

    1. Aaronson ST, Van Der Vaart A, Miller T, LaPratt J, Swartz K, Shoultz A, Lauterbach M, Sackeim HA, Suppes T (2023) Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized controlled trial. JAMA Psychiatry 81:555–562. https://doi.org/10.1001/jamapsychiatry.2023.4685 - DOI
    1. American Psychedelic Practitioners Association (2023) Professional practice guidelines for psychedelic-assisted therapy. https://www.appa-us.org/standards-and-guidelines/professionalpracticegui...
    1. Anastasopoulos G, Photiades H (1962) Effects of LSD-25 on relatives of schizophrenic patients. J Ment Sci 108:95–98. https://doi.org/10.1192/bjp.108.452.95 - DOI
    1. Appelbaum PS (2007) Assessment of patients’ competence to consent to treatment. N Engl J Med 357:1834–1840
    1. Barber G, Nemeroff CB, Siegel S (2022) A case of prolonged mania, psychosis, and severe depression after psilocybin use: implications of increased psychedelic drug availability. Am J Psychiatry 179:892–896. https://doi.org/10.1176/appi.ajp.22010073 - DOI

LinkOut - more resources